Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Collection

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

Abstract

Auto-SCT has been shown to be a potentially curative treatment for a variety of hematological malignancies. Auto-SCT is dependent on the successful mobilization and collection of hematopoietic stem cells to ensure engraftment. The inability to mobilize sufficient number of hematopoietic stem cells using standard cytokine-assisted mobilization strategies excludes eligible patients from potentially curative auto-SCT. Plerixafor (AMD3100; Mozobil), a novel bicyclam antagonist of the SDF-1α/CXCR4 complex, has been reported previously to augment PBSC mobilization in patients undergoing their first planned stem cell mobilization and collection attempt. In our experience, 17 of 20 patients otherwise eligible for auto-SCT who failed previous mobilization attempts had successful mobilization of CD34+ hematopoietic stem cells with one apheresis procedure, and an additional patient required two aphereses procedures, when treated with the combination of plerixafor and G-CSF on a compassionate use protocol available at our institution.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003; 21: 759–806.

    Article  CAS  PubMed  Google Scholar 

  2. Ng-Cashin J, Shen T . Mobilization of autologous peripheral blood hematopoietic cells for support of high-dose cancer therapy. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas’ Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing, Ltd.: Malden, MA, USA, 2004, pp 576–587.

    Google Scholar 

  3. Freuhauf S, Seggewiss R . It's moving day: factors affecting peripheral blood stem mobilization and strategies for improvement. Br J Haematol 2003; 122: 360–372.

    Article  Google Scholar 

  4. Allan DS, Keeney M, Howson-Jan K, Poma J, Weir K, Bhatia M et al. Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967–972.

    Article  CAS  PubMed  Google Scholar 

  5. Villalon L, Odriozola J, Larana JG, Zamora C, Perez de Oteyza J, Jodra MH et al. Autologous peripheral blood progenitor transplantation with <2 × 106 CD34+/kg: an analysis of variables concerning mobilization and engraftment. Hematol J 2000; 1: 374–381.

    Article  CAS  PubMed  Google Scholar 

  6. Tomblyn M, Burns LJ, Blazar B, Wagner J, Lee C, Rogers T et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant 2007; 40: 111–118.

    Article  CAS  PubMed  Google Scholar 

  7. Oelshlaegel U, Bornhauser M, Boxberger S, Kroschinsky F, Illmer T, Hoelig K et al. Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilization with G-CSF plus AMD3100 in patients with multiple myeloma. Ann Hematol 2007; 86: 569–573.

    Article  Google Scholar 

  8. Hatse S, Princen K, Bridger G, DeClercq E, Schols D . Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002; 527: 262.

    Article  Google Scholar 

  9. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW . Molecular interactions of cylcam and bicyclam non-peptide antagonists with CXCR4 chemokine receptor. J Biol Chem 2001; 276: 14153–14160.

    Article  CAS  PubMed  Google Scholar 

  10. Shen H, Cheng T, Olszak I, Garcia-Zepeda E, Lu Z, Herrmann S et al. CXCR-4 desensitization is associated with tissue localization of hemopoietic progenitor cells. J Immunol 2001; 166: 5027–5033.

    Article  CAS  PubMed  Google Scholar 

  11. Link DC . Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol Res 2005; 32: 169–178.

    Article  CAS  PubMed  Google Scholar 

  12. Liesveld JL, Bechelli J, Rosell K, Lu C, Bridger G, Phillips II G et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 2007; 31: 1553–1563.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667–1673.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al., AMD3100 HIV Study Group. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Accquir Immune Defic Syndr 2004; 37: 1253–1262.

    Article  CAS  Google Scholar 

  15. Hubel K, Liles WC, Broxmeyer HE, Rodger E, Wood B, Cooper S et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004; 1: 165–172.

    Article  PubMed  Google Scholar 

  16. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728–2730.

    Article  CAS  PubMed  Google Scholar 

  17. Broxmeyer HE, Hangoc G, Cooper S, Campbell T, Ito S, Mantel C . AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis. Ann N Y Acad Sci 2007; 1106: 1–19.

    Article  CAS  PubMed  Google Scholar 

  18. Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with G-CSF by single dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295–300.

    Article  CAS  PubMed  Google Scholar 

  19. Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.

    Article  CAS  PubMed  Google Scholar 

  20. Cashen AF, Lazarus HM, Devine SM . Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant 2007; 39: 577–588.

    Article  CAS  PubMed  Google Scholar 

  21. Flomenberg N, Dipersio J, Calandra G . Role of CXR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematologica 2005; 114: 198–205.

    Article  CAS  PubMed  Google Scholar 

  22. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095–1102.

    Article  CAS  PubMed  Google Scholar 

  23. Flomenberg N, DiPersio J, Liesveld J, McCarty J, Rowley S, Vesole D et al. AMD3100+G-CSF hematopoietic progenitor cell (HPC) mobilization is safe, effective, and superior to mobilization with G-CSF alone. [oral session] American Society of Hematology: San Diego, CA, USA, 2003.

  24. Holtan SG, Porrata LF, Micallef IN, Padley DJ, Inwards DJ, Ansell SA et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 7: 315–318.

    Article  CAS  PubMed  Google Scholar 

  25. Dugan MJ, Akard LP, Thompson JM, Nademanee A, Maziarz RT, Bensinger WI et al. Treatment with AMD3100 in multiple myeloma or non-Hodgkin's lymphoma patients to increase the number of peripheral blood stem cells when given with a mobilizing regimen of chemotherapy and G-CSF. [poster P 503] Annual Meeting of the European Group for Blood and Marrow Transplantation 31st 2005 (submitted).

  26. Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Flomenberg N, Weisdorf D et al. AMD3100 plus G-CSF rapidly mobilizes hematopoietic progenitor cells in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM), including those traditionally considered poor mobilizers. [abstract 271] Tandem BMT Meeting: Keystone, CO, USA, 2005.

  27. Roberts CH, Chung HM, Candler KS, Calandra G, Badel K, McCarty JM . Single-center experience with the early use of AMD3100 plus G-CSF for mobilization of hematopoietic progenitor cells in patients classified as poor mobilizers. [abstract 99] Tandem BMT Meeting: Keystone, CO, USA, 2007.

    Article  Google Scholar 

  28. Calandra G, McCarty J, McGuirk J, Barlogie B, Crocker S-A, Badel K . AMD3100 plus G-CSF mobilizes the majority of non-Hodgkins lymphoma (NHL), multiple myeloma (MM), and Hodgkin’s disease (HD) patients who failed prior mobilization with other regimens. Bone Marrow Transplant 2008; 41: 331–338.

    Article  CAS  PubMed  Google Scholar 

  29. Maziarz RT, Dunn A, Hansen L, Hansen K, Leis JF, Hayes-Lattin B et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and AMD3100: an institutional experience. [abstract 5460] American Society of Hematology: Orlando, FL, USA, 2006.

  30. DiPersio J, Stadtmauer EA, Nademanee AP, Stiff P, Micallef I, Angell J et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (plerixfor)+G-CSF vs G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. [abstract 445] American Society of Hematology: Atlanta, GA, USA, 2007.

  31. DiPersio J, Micallef I, Stiff P, Bolwell B, Maziarz RT, Angell J et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (plerixfor)+G-CSF vs G-CSF+placebo for mobilization in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. [abstract 601] American Society of Hematology: Atlanta, GA, USA, 2007.

  32. Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996; 36: 585–589.

    Article  Google Scholar 

  33. Dermirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937–941.

    Google Scholar 

  34. Haas R, Murea S . The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells. Cytokines Mol Ther 1995; 1: 249–270.

    CAS  PubMed  Google Scholar 

  35. Amgen Inc.. Nupogen. Physician's Desk Reference, 60th edn. Thomson PDR: Montvale, NJ, USA, 2006, pp 598–603.

Download references

Acknowledgements

We thank Binnie Grant and the late Dan Callaway for their assistance in data management of patients on this protocol.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R T Maziarz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fowler, C., Dunn, A., Hayes-Lattin, B. et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 43, 909–917 (2009). https://doi.org/10.1038/bmt.2008.409

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.409

Keywords

This article is cited by

Search

Quick links